Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer

  • Technology appraisal guidance
  • TA944
  • Published: 
Download guidance (PDF)

2 Information about durvalumab plus gemcitabine and cisplatin

Marketing authorisation indication

2.1

Durvalumab (Imfinzi, AstraZeneca) in combination with gemcitabine and cisplatin is indicated for 'the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer'.

Dosage in the marketing authorisation

Price

2.3

The list price of durvalumab is £2,466 for a 500 mg per 10 ml vial (excluding VAT; BNF online, accessed October 2023).

2.4

The company has a commercial arrangement. This makes durvalumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.